CorMedix’s CRMD lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver. The FDA approved DefenCath in late 2023 as the first and only antimicrobial ...

CorMedix CRMD has been riding on the success of its lead product, DefenCath (taurolidine plus heparin), which was approved by the FDA in 2023 as the first and only antimicrobial catheter lock solution ...

FY25 profit surge, discounted valuation, and ReSPECT Phase III Rezzayo catalyst in Q2 2026. Click for this CRMD update.

The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...

CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in late 2023 as the ...

DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...

The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...

CorMedix raised its second-quarter sales forecast on Monday after disclosing that its large dialysis organization (LDO) partner has started implementing DefenCath with a broader reach than previously ...

BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (CRMD) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...